By Professor Richard Bryan Lock

Journal articles

Bruedigam C; Bagger FO; Heidel FH; Paine Kuhn C; Guignes S; Song A; Austin R; Vu T; Lee E; Riyat S; Moore AS; Lock RB; Bullinger L; Hill GR; Armstrong SA; Williams DA; Lane SW, 2014, 'Telomerase inhibition effectively targets mouse and human AML stem cells and delays relapse following chemotherapy', Cell Stem Cell, 15, pp. 775 - 790, http://dx.doi.org/10.1016/j.stem.2014.11.010

Carol H; Maris JM; Kang MH; Reynolds CP; Kolb EA; Gorlick R; Keir ST; Wu J; Lyalin D; Kurmasheva RT; Houghton PJ; Smith MA; Lock RB, 2014, 'Initial Testing (Stage 1) of the Notch Inhibitor PF-03084014, by the Pediatric Preclinical Testing Program (vol 61, pg 1493, 2014)', PEDIATRIC BLOOD & CANCER, 61, pp. 1716 - 1716, http://dx.doi.org/10.1002/pbc.25186

Kang MH; Reynolds CP; Maris JM; Gorlick R; Kolb EA; Lock R; Carol H; Keir ST; Wu J; Lyalin D; Kurmasheva RT; Houghton PJ; Smith MA, 2014, 'Initial testing (stage 1) of the investigational mTOR kinase inhibitor MLN0128 by the pediatric preclinical testing program', Pediatric Blood and Cancer, 61, pp. 1486 - 1489, http://dx.doi.org/10.1002/pbc.24989

Carol H; Maris JM; Kang MH; Reynolds CP; Kolb EA; Gorlick R; Keir ST; Wu J; Kurmasheva RT; Houghton PJ; Smith MA; Lock RB, 2014, 'Initial testing (stage 1) of the notch inhibitor PF-03084014, by the pediatric preclinical testing program', Pediatric Blood and Cancer, 61, pp. 1493 - 1496, http://dx.doi.org/10.1002/pbc.25026

Wong NC; Bhadri VA; Maksimovic J; Parkinson-Bates M; Ng J; Craig JM; Saffery R; Lock RB, 2014, 'Stability of gene expression and epigenetic profiles highlights the utility of patient-derived paediatric acute lymphoblastic leukaemia xenografts for investigating molecular mechanisms of drug resistance', BMC Genomics, 15, pp. 416, http://dx.doi.org/10.1186/1471-2164-15-416

Lu H; Kojima K; Battula VL; Korchin B; Shi Y; Chen Y; Spong S; Thomas DA; Kantarjian H; Lock RB; Andreeff M; Konopleva M, 2014, 'Targeting connective tissue growth factor (CTGF) in acute lymphoblastic leukemia preclinical models: Anti-CTGF monoclonal antibody attenuates leukemia growth', Annals of Hematology, 93, pp. 485 - 492, http://dx.doi.org/10.1007/s00277-013-1939-2

Samuels AL; Beesley AH; Yadav BD; Papa RA; Sutton R; Anderson D; Marshall GM; Cole CH; Kees UR; Lock RB, 2014, 'A pre-clinical model of resistance to induction therapy in pediatric acute lymphoblastic leukemia', Blood Cancer Journal, 4, pp. e232 - e232, http://dx.doi.org/10.1038/bcj.2014.52

Shahbazi J; Scarlett CJ; Norris MD; Liu B; Haber M; Tee AE; Carrier A; Biankin AV; London WB; Marshall GM; Lock RB; Liu T, 2014, 'Histone Deacetylase 2 and N-Myc reduce p53 protein phosphorylation at serine 46 by repressing gene transcription of tumor protein 53-induced nuclear protein 1', Oncotarget, 5, pp. 4257 - 4268, http://dx.doi.org/10.18632/oncotarget.1991

Jamieson WRAB; Jing D; El-Hoss J; Lock R; MacKenzie K, 2014, 'A novel fluorometric assay for aldo-keto reductase 1C3 predicts metabolic activation of the nitrogen mustard prodrug PR-104A in human leukaemia cells', Biochemical Pharmacology, 88, pp. 36 - 45, http://dx.doi.org/10.1016/j.bcp.2013.12.019

Suryani S; Carol H; Chonghaile TN; Frismantas V; Sarmah C; High L; Bornhauser B; Cowley MJ; Szymanska B; Evans K; Boehm I; Tonna E; Jones L; Manesh DM; Kurmasheva RT; Billups C; Kaplan W; Letai A; Bourquin JP; Houghton PJ; Smith MA; Lock RB, 2014, 'Cell and molecular determinants of in vivo efficacy of the BH3 mimetic ABT-263 against pediatric acute lymphoblastic leukemia xenografts', Clin Cancer Res, 20, pp. 4520 - 4531, http://dx.doi.org/10.1158/1078-0432.CCR-14-0259

Gorlick R; Kolb EA; Maris JM; Reynolds CP; Kang MH; Carol H; Lock RB; Billups CA; Kurmasheva RT; Houghton PJ; Smith MA; Keir ST, 2014, 'Initial testing (stage 1) of the polo-like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program', Pediatric Blood and Cancer, 61, pp. 158 - 164, http://dx.doi.org/10.1002/pbc.24616

Lock RB; Busfield S; Biondo M; Wong M; Ramshaw H; Lee E; Ghosh S; Braley H; Panousis C; Roberts A; He S; Thomas D; Fabri L; Vairo G; Lock REA, 2014, 'Targeting of acute myeloid leukemia in vitro and in vivo with an anti-CD123 mAb engineered for optimal ADCC', Leukemia, advance online publication, 9 May 2014, pp. 2213 - 2221, http://dx.doi.org/10.1038/leu.2014.128

Waibel M; Solomon VS; Knight DA; Ralli RA; Kim SK; Banks KM; Vidacs E; Virely C; Sia KCS; Bracken LS; Collins-Underwood R; Drenberg C; Ramsey LB; Meyer SC; Takiguchi M; Dickins RA; Levine R; Ghysdael J; Dawson MA; Lock RB; Mullighan CG; Johnstone RW, 2013, 'Combined Targeting of JAK2 and Bcl-2/Bcl-xL to Cure Mutant JAK2-Driven Malignancies and Overcome Acquired Resistance to JAK2 Inhibitors', Cell Reports, 5, pp. 1047 - 1059, http://dx.doi.org/10.1016/j.celrep.2013.10.038

Carol H; Gorlick R; Kolb EA; Morton CL; Moradi Manesh D; Keir ST; Reynolds CP; Kang MH; Maris JM; Wozniak A; Hickson I; Lyalin D; Kurmasheva RT; Houghton PJ; Smith MA; Lock R, 2013, 'Initial testing (stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ-26481585), by the Pediatric Preclinical Testing Program', Pediatric Blood & Cancer, 61, pp. 245 - 252, http://dx.doi.org/10.1002/pbc.24724

Oram SH; Thoms J; Sive J; Calero-Nieto FJ; Kinston SJ; Schuette J; Knezevic K; Lock RB; Pimanda JE; Gottgens B, 2013, 'Bivalent promoter marks and a latent enhancer may prime the leukaemia oncogene LMO1 for ectopic expression in T-cell leukaemia', Leukemia, 27, pp. 1348 - 1357, http://dx.doi.org/10.1038/leu.2013.2

Piazza RG; Magistroni V; Mogavero A; Andreoni F; Ambrogio C; Chiarle R; Mologni L; Bachmann PS; Lock RB; Collini P; Pelosi G; Gambacorti-Passerini C, 2013, 'Epigenetic silencing of the proapoptotic gene BIM in anaplastic large cell lymphoma through an MeCP2/SIN3a deacetylating complex', Neoplasia, 15, pp. 511 - 522, http://dx.doi.org/10.1593/neo.121784

Malyukova A; Papa R; O'Brien R; Giles JE; Trahair TN; Pozza LD; Sutton R; Liu T; Haber M; Norris MD; Lock RB; Marshall GM; Giles J, 2013, 'FBXW7 regulates glucocorticoid response in T-cell acute lymphoblastic leukaemia by targeting the glucocorticoid receptor for degradation', Leukemia, 27, pp. 1053 - 1062, http://dx.doi.org/10.1038/leu.2012.361

Lock RB; Carol H, 2013, 'Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the Pediatric Preclinical Testing Program', Pediatric Blood and Cancer, 60, pp. 1325 - 1332, http://dx.doi.org/10.1002/pbc.24517

Lock RB; Carol H, 2013, 'Initial testing (stage 1) of ganetespib, an Hsp90 inhibitor, by the Pediatric Preclinical Testing Program', Pediatric Blood and Cancer, 60, pp. E42 - E45, http://dx.doi.org/10.1002/pbc.24451

Lock RB; Carol H, 2013, 'Initial Testing (Stage 1) of Temozolomide by the Pediatric Preclinical Testing Program', Pediatric Blood and Cancer, 60, pp. 783 - 790, http://dx.doi.org/10.1002/pbc.24368

Lock RB; Carol H, 2013, 'Initial testing (stage 1) of the phosphatidylinositol 3’ kinase inhibitor, SAR245408 (XL147) by the Pediatric Preclinical Testing Program', Pediatric Blood and Cancer, 60, pp. 791 - 798, http://dx.doi.org/10.1002/pbc.24301

Lock RB; Ekert P, 2013, 'Targeting acute myeloid leukemia by dual inhibition of P13K signalling and Cdk9-mediated Mcl-1 transcription', Blood, 122, pp. 738 - 748, http://dx.doi.org/10.1182/blood-2012-08-447441

Lock RB; Carol H; Szymanska B; Boehm I, 2013, 'The anti-CD19 antibody-drug conjugate SAR3419 prevents hematolymphoid relapse post induction therapy in preclinical models of pediatric acute lymphoblastic leukemia', Clinical Cancer Research, 19, pp. 1795 - 1805, http://dx.doi.org/10.1158/1078-0432.CCR-12-3613

Shahbazi J; Lock RB; Liu T, 2013, 'Tumor protein 53-induced nuclear protein 1 enhances p53 function and represses tumorigenesis', Frontiers in Genetics, 13, pp. Art. No. 80, http://dx.doi.org/10.3389/fgene.2013.00080

Kan C; Petti C; Bracken L; Maritz M; Xu N; O'Brien R; Yang C; Liu T; Yuan J; Lock RB; Mackenzie KL, 2013, 'Up-regulation of survivin during immortalization of human myofibroblasts is linked to repression of tumor suppressor p16(INK4a) protein and confers resistance to oxidative stress', The Journal of Biological Chemistry, 288, pp. 12032 - 12041, http://dx.doi.org/10.1074/jbc.M112.447821

, 2012, 'Correction: Disparate In Vivo Efficacy of FTY720 in Xenograft Models of Philadelphia Positive and Negative B-lineage Acute Lymphoblastic Leukemia', PloS one, 7

Lock RB; Don A; Qiao Q, 2012, 'Disparate in vivo efficacy of FTY720 in xenograft models of Philadelphia positive and negative B-lineage acute lymphoblastic leukemia', PLoS ONE, 7, pp. e36429, http://dx.doi.org/10.1371/journal.pone.0036429

Smith MA; Maris JM; Gorlick R; Kolb EA; Lock R; Carol H; Keir ST; Reynolds CP; Kang MH; Morton CL; Wu J; Smith PG; Yu J; Houghton PJ, 2012, 'Erratum: Malcolm A. Smith, John M. Maris, Richard Gorlick, E. Anders Kolb, Richard Lock, Hernan Carol, Stephen T. Keir, C. Patrick Reynolds, Min H. Kang, Christopher L. Morton, Jianrong Wu, Peter G. Smith, Jie Yu and Peter J. Houghton. Initial testing of the investigational NEDD8‐activating enzyme inhibitor MLN4924 by the pediatric preclinical testing program. Pediatr Blood Cancer. 2012 August; 59(2):246‐253', Pediatric Blood & Cancer, 59, pp. 772 - 772, http://dx.doi.org/10.1002/pbc.24291

Bhadri V; Trahair TN; Lock RB; bhadri , 2012, 'Glucocorticoid resistance in paediatric acute lymphoblastic leukaemia', Journal of Paediatrics and Child Health, 48, pp. 634 - 640, http://dx.doi.org/10.1111/j.1440-1754.2011.02212.x

Markovic A; Mackenzie K; Lock RB, 2012, 'Induction of Vascular Endothelial growth factor secretion by childhood acute lymphoblastic leukemia cells via the FLT-3 signaling pathway', Molecular Cancer Therapeutics, 11, pp. 183 - 193, http://dx.doi.org/10.1158/1535-7163.MCT-11-0503

Kolb EA; Gorlick R; Keir ST; Maris JM; Lock RB; Carol H; Kurmasheva RT; Reynolds CP; Kang MH; Wu J; Houghton PJ; Smith MA, 2012, 'Initial testing (stage 1) by the pediatric preclinical testing program of RO4929097, a gamma-secretase inhibitor targeting notch signaling', Pediatric Blood and Cancer, 58, pp. 815 - 818, http://dx.doi.org/10.1002/pbc.23290

Kang MH; Reynolds CP; Houghton PJ; Alexander D; Morton CL; Kolb EA; Gorlick R; Keir ST; Carol H; Lock RB; Maris JM; Wozniak A; Smith MA, 2012, 'Initial testing (Stage 1) of AT13387, an HSP90 inhibitor, by the pediatric preclinical testing program', Pediatric Blood and Cancer, 59, pp. 185 - 188, http://dx.doi.org/10.1002/pbc.23154

Houghton PJ; Kang MH; Reynolds CP; Morton CL; Kolb EA; Gorlick R; Keir ST; Carol H; Lock RB; Maris JM; Billups CA; Smith MA, 2012, 'Initial testing (stage 1) of LCL161, a SMAC mimetic, by the pediatric preclinical testing program', Pediatric Blood and Cancer, 58, pp. 636 - 639, http://dx.doi.org/10.1002/pbc.23167

Batra V; Maris JM; Kang MH; Reynolds CP; Houghton PJ; Alexander D; Kolb EA; Gorlick R; Keir ST; Carol H; Lock RB; Billups CA; Smith MA, 2012, 'Initial testing (stage 1) of SGI-1776, a PIM1 kinase inhibitor, by the pediatric preclinical testing program', Pediatric Blood and Cancer, 59, pp. 749 - 752, http://dx.doi.org/10.1002/pbc.23364

Gorlick R; Kolb EA; Houghton PJ; Morton CL; Neale G; Keir ST; Carol H; Lock RB; Phelps D; Kang MH; Reynolds CP; Maris JM; Billups C; Smith MA, 2012, 'Initial testing (stage 1) of the cyclin dependent kinase inhibitor SCH 727965 (dinaciclib) by the pediatric preclinical testing program', Pediatric Blood and Cancer, 59, pp. 1266 - 1274, http://dx.doi.org/10.1002/pbc.24073

Houghton PJ; Gorlick R; Kolb EA; Lock RB; Carol H; Morton CL; Keir ST; Reynolds CP; Kang MH; Phelps D; Maris JM; Billups C; Smith MA, 2012, 'Initial testing (stage 1) of the mTOR kinase inhibitor AZD8055 by the pediatric preclinical testing program', Pediatric Blood and Cancer, 58, pp. 191 - 199, http://dx.doi.org/10.1002/pbc.22935

Smith MA; Gorlick R; Kolb EA; Lock RB; Carol H; Maris JM; Keir ST; Morton CL; Reynolds CP; Kang MH; Arts J; Bashir T; Janicot M; Kurmasheva RT; Houghton PJ, 2012, 'Initial testing of JNJ-26854165 (Serdemetan) by the pediatric preclinical testing program', Pediatric Blood and Cancer, 59, pp. 329 - 332, http://dx.doi.org/10.1002/pbc.23319

Lock RB; Carol H; Morton CL; Keir ST; Reynolds CP; Kang MH; Maris JM; Wozniak AW; Gorlick R; Kolb EA; Houghton PJ; Smith MA, 2012, 'Initial testing of the CENP-E inhibitor GSK923295A by the pediatric preclinical testing program', Pediatric Blood and Cancer, 58, pp. 916 - 923, http://dx.doi.org/10.1002/pbc.23176

Smith MA; Maris JM; Gorlick R; Kolb EA; Lock RB; Carol H; Keir ST; Reynolds CP; Kang MH; Morton CL; Wu J; Smith PG; Yu J; Houghton PJ, 2012, 'Initial testing of the investigational NEDD8-activating enzyme inhibitor MLN4924 by the pediatric preclinical testing program', Pediatric Blood and Cancer, 59, pp. 246 - 253, http://dx.doi.org/10.1002/pbc.23357

Lock RB; Carol H, 2012, 'Initial testing of the MDM2 inhibitor RG7112 by the Pediatric Preclinical Testing Program', Pediatric Blood and Cancer, 60, pp. 633 - 641, http://dx.doi.org/10.1002/pbc.24235

Szymanska B; Wilczynska-Kalak U; Kang M; Liem N; Carol H; Boehm I; Groepper D; Reynolds CP; Stewart C; Lock RB; Ingrid , 2012, 'Pharmacokinetic modeling of an induction regimen for in vivo combined testing of novel drugs against pediatric acute lymphoblastic leukemia xenografts', PLoS One, 7, pp. Article number e33894, http://dx.doi.org/10.1371/journal.pone.0033894

Frolova O; Samudio I; Benito J; Jacamo R; Kornblau SM; Markovic A; Schober W; Lu H; Qiu YH; Buglio D; Mcqueen T; Pierce S; Shpall E; Konoplev S; Thomas D; Kantarjian H; Lock RB; Andreeff M; Konopleva M, 2012, 'Regulation of HIF-1 alpha signaling and chemoresistance in acute lymphocytic leukemia under hypoxic conditions of the bone marrow microenvironment', Cancer Biology and Therapy, 13, pp. 858 - 870, http://dx.doi.org/10.4161/cbt.20838

Gorlick R; Maris JM; Houghton PJ; Lock RB; Carol H; Kurmasheva RT; Kolb EA; Reynolds CP; Kang MH; Billups CA; Smith MA, 2012, 'Testing of the Akt/PKB inhibitor MK-2206 by the pediatric preclinical testing program', Pediatric Blood and Cancer, 59, pp. 518 - 524, http://dx.doi.org/10.1002/pbc.23412

Houghton PJ; Lock RB; Carol H; Morton CL; Gorlick R; Kolb EA; Keir ST; Reynolds CP; Kang MH; Maris JM; Billups C; Zhang MX; Madden SL; Teicher BA; Smith MA, 2012, 'Testing of the topoisomerase 1 inhibitor Genz-644282 by the pediatric preclinical testing program', Pediatric Blood and Cancer, 58, pp. 200 - 209, http://dx.doi.org/10.1002/pbc.23016

Lu H; Battula VL; Shi Y; Lock RB; Spong S; Andreeff M; Konopleva M, 2011, 'Role of Connective Tissue Growth Factor (CTGF) in Survival and Chemosensitivity of Acute Lymphoblastic Leukemia', Blood, 118, pp. 2593 - 2593, http://dx.doi.org/10.1182/blood.v118.21.2593.2593

Pimanda J; Thoms J; Birger Y; Foster S; Knezevic K; Kirschenbaum Y; Chandrakanthan V; Lock R; MacKenzie K; Gottgens B; Izraeli S, 2011, 'ERG PROMOTES T-ACUTE LYMPHOBLASTIC LEUKEMIA AND IS TRANSCRIPTIONALLY REGULATED IN LEUKEMIC CELLS BY A STEM CELL ENHANCER', EXPERIMENTAL HEMATOLOGY, 39, pp. S108 - S108, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000293801700179&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Smith MPW; Wood SL; Zougman A; Ho JTC; Peng J; Jackson D; Cairns DA; Lewington AJP; Selby PJ; Banks RE, 2011, 'A systematic analysis of the effects of increasing degrees of serum immunodepletion in terms of depth of coverage and other key aspects in top-down and bottom-up proteomic analyses.', Proteomics, 11, pp. 2222 - 2235, http://dx.doi.org/10.1002/pmic.201100005

Carol H; Boehm I; Reynolds CP; Kang MH; Maris JM; Morton CL; Gorlick R; Kolb EA; Keir ST; Wu J; Wozniak AE; Yang Y; Manfredi M; Ecsedy J; Wang J; Neale G; Houghton PJ; Smith MA; Lock RB, 2011, 'Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer', Cancer Chemotherapy and Pharmacology, 68, pp. 1291 - 1304, http://dx.doi.org/10.1007/s00280-011-1618-8

Thoms JAI; Birger Y; Foster S; Knezevic K; Kirshenbaum Y; Chandrakanthan V; Jonquieres G; Spensberger D; Wong JW; Oram SH; Kinston SJ; Groner Y; Lock RB; MacKenzie KL; Gottgens B; Izraeli S; Pimanda JE, 2011, 'ERG promotes T-acute lymphoblastic leukemia and is transcriptionally regulated in leukemic cells by a stem cell enhancer', Blood, 117, pp. 7079 - 7089, http://dx.doi.org/10.1182/blood-2010-12-317990

Bhadri V; Cowley MJ; Kaplan W; Trahair TN; Lock RB, 2011, 'Evaluation of the NOD/SCID xenograft model for glucocorticoid-regulated gene expression in childhood B-cell precursor acute lymphoblastic leukemia', BMC Genomics, 12, pp. 1 - 13, http://dx.doi.org/10.1186/1471-2164-12-565

Back to profile page